ATLAS Biolabs GmbH Joins Roche NimbleGen’s Certified Service Provider Program for Targeted Enrichment
News Feb 05, 2010
Roche NimbleGen has announced that ATLAS Biolabs GmbH, a Berlin, Germany-based company, has officially become a Certified Service Provider (CSP) for NimbleGen Sequence Capture. They will provide services for NimbleGen 454 Optimized Sequence Capture Arrays coupled with sequencing services on the Genome Sequencer FLX System from 454 Life Sciences, a Roche Company.
ATLAS Biolabs GmbH has passed a rigorous certification test plan to achieve precise experimental standards to officially join the Roche NimbleGen Certified Service Provider Program. Their certification marks the second genomic service provider to join the Roche NimbleGen CSP Program for Sequence Capture in Europe. They will process customer gDNA samples for genomic enrichment, using the complete NimbleGen Sequence Capture workflow optimized for 454 GS FLX Titanium Series sequencing using 385K Arrays and 2.1M Array.
“The decision to join the Roche NimbleGen CSP Program was a logical extension of our portfolio. Our customers are looking at targeted genomic sequencing and we wanted to provide them with a set of elite solutions for the necessary enrichment” said Prof. Dr. Peter Nurnberg, CEO of ATLAS Biolabs GmbH.
“Roche NimbleGen welcomes the latest addition, ATLAS Biolabs GmbH, to our CSP family for Sequence Capture. ATLAS Biolab’s close ties with key opinion leaders across several key market segments in Germany, in addition to their established academic excellence, will further strengthen our position as a leader in the targeted resequencing market and drive future growth of the Roche NimbleGen business and service channel in Europe," said Jay Schiestle, Vice President of Manufacturing for Roche NimbleGen, Inc.
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE
Improved Method for Isolating Extracellular RNANews
In a breakthrough that could lead to powerful new ways to diagnose and track a wide range of medical conditions, scientists at The Rockefeller University have devised an improved method for isolating and identifying tiny fragments of RNA in human blood products.READ MORE